ClinicalTrials.Veeva

Menu

Immune Profiling for Cancer Immunotherapy Response

Dartmouth Health logo

Dartmouth Health

Status

Enrolling

Conditions

Hematologic Malignancy
Blood Cancer
Cancer
Tumor, Solid

Treatments

Diagnostic Test: Methylation Cytometry

Study type

Observational

Funder types

Other

Identifiers

NCT06116032
Study02001227

Details and patient eligibility

About

In patients clinically treated with FDA-approved immunotherapy the investigators will assess the predictive value of pre- and on-treatment 1) immune-methylation profiling across cancer types, and 2) immune-methylation profiling and cytokine profiling within cancer types.

Enrollment

1,500 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Cancer patients receiving or will receive immunotherapy under FDA- approved indication (e.g. checkpoint inhibitor therapy with pembrolizumab, nivolumab, or ipilimumab, or cellular immunotherapy).
  • Participants are eligible regardless of the type of prior therapy (i.e. prior immunotherapy treated participants can be included).

Exclusion criteria

  • Pregnant women/fetuses/neonates
  • Prisoners
  • Decision-impaired individuals

Trial design

1,500 participants in 3 patient groups

Standard of Care Checkpoint
Description:
Patients receiving standard of care FDA approved immunotherapy
Treatment:
Diagnostic Test: Methylation Cytometry
Bone Marrow Transplant
Description:
Patients undergoing transplant for hematologic malignancy
Treatment:
Diagnostic Test: Methylation Cytometry
CAR T
Description:
Patients undergoing CAR T therapy
Treatment:
Diagnostic Test: Methylation Cytometry

Trial contacts and locations

1

Loading...

Central trial contact

Hannah G Stolrow, BA; Brock C Christensen, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems